Macular degeneration neovascular

Ferrara N, Damico L, Shams N, et al (2006) Developmemt of Ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26 859-870... 

Drusen ablation may help patients with multiple large drusen in both eyes that have not progressed to neovascular macular degeneration. These laser treatments may lead to resolution of the drusen and improved visual acuity. However, it is not clear if progression to choroidal neovascular membranes and neovascular macular degeneration is reduced.23 There is a possibility that the laser treatments may induce choroidal neovascularization and retinal atrophy.22... 

EDCC Study Group (1993). Antioxidant status and neovascular age-related macular degeneration. Arch. Ophthalmol. Ill 104—109. 

Snellen, E. L., A. L. Verbeek et al. (2002). Neovascular age-related macular degeneration and its relationship to antioxidant intake. Acta Ophthalmol. Scand. 80(4) 368-371. 

Campa C, Harding SP (2011) Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets 12 173-181... 

Lucentis contains ranibizumab and is available for intravitreal injection. It is a vascular endothelial growth factor inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration. Unlike verteporfin, which is used in photodynamic treatment of age-related macular degeneration, ranibizumab does not require activation by local irradiation using non-thermal red light. 

The only modality which is in daily and widespread routine cHnical practice so far is the imaging of ocular diseases in ophthalmology. Fluorescein and ICG are established as fluorescent agents to enhance visuaHzation of chorioretinal diseases, such as vascular disorders, rethinopathies, neovascularization (age-related macular degeneration) or tumours [130,134,135]. 

Mechanism of Action-. A selective vascular endothelial growth factor (VEGF) antagonize that selectively binds and activates receptors located on the surface of vascular endothelial cells. Therapeutic Effect Blocks angiogenesis and vascular permeability and inflammation which contribute to the progression of the neovascular (wet) form of age-related macular degeneration (AMD). 

Pegaptinib Sodium Injeotion For neovascular (wet) age related macular degeneration... 

Neovascular macular degeneration Ranibizumab (labeled), bevacizumab (unlabeled) Fair... 

Uses Neovascular wet macular degeneration Action Vascular endothelial growth factor inhibitor Dose 0.5 mg intravitreal inj qmo Caution [C ] Hx thromboembolism Contra Periocular Infxn Disp Inj SE Endophthalmitis, retinal detachment/hemorrhage, cataract, intraocular inflammation, conjunctival hemorrhage, eye pain, floaters EMS None OD Unlikely, but immediate effect would be vision loss and pain d/t T ocular pressure... 

Pathologic neovascularization of the retina is central to several debilitating ocular diseases including proliferative diabetic retinopathy (PDR), age-related macular degeneration (AMD), and retinopathy of prematurity (ROP). Diabetic retinopathy (primarily retinal NV) and the wet form of AMD (primarily choroidal NY) are the leading causes of blindness in developed countries. 

Vine AK, Brewer GJ. Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Trans Am Ophthalmol Soc 2002 100 73-76 discussion 76-77. 

Choroidal neovascularization associated with age-related macular degeneration is difficult to treat with conventional laser procedures because normal retinal tissues can be destroyed, which results in loss of central vision. Photodynamic therapy offers the opportimity to selectively eradicate neovascular membranes while producing minimal damage to normal retinal and choroidal tissues. 

---